Campath

Phase 1Small molecule

Sanofi

Campath is one of 82 small molecule programs targeting Systemic Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic SclerosisActive, not recruiting

Sickle Cell DiseaseRecruiting

Systemic SclerosisPreclinical

Active, not recruiting

Sickle Cell DiseasePhase 1

Recruiting

Competition

Competitive Landscape

98 competitors in Sickle Cell Disease

#DrugCompanyPhaseTrials

Campath

GGenzyme, a Sanofi Company

Phase 3

13 2

Ritalin

Novartis

Phase 3

2 3

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

4 4

Toradol

JJavelin Pharmaceuticals

Phase 3

2 5

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

1 6

Cellcept

Roche

Phase 2

6 7

PIASKY

Roche

Phase 3

2 8

Tepadina

Jazz Pharmaceuticals

Phase 2

4 9

Rapamune

PPrism Pharmaceuticals

Orencia

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 1Recruiting

Sickle Cell Disease

NCT07015684

Clinical

Trials by Indication[1]

Allogeneic Stem Cell Transplantation3 trials

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Completed·UUniversity of Chicago·Phase 2·NCT00683046·204 enrolled

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Terminated·UUniversity of Chicago·Phase 1·NCT00943293·1 enrolled

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Completed·UUniversity of Chicago·Phase 1/2·NCT00943319·50 enrolled

Chronic Lymphocytic Leukemia2 trials

Campath Maintenance in Chronic Lymphocytic Leukemia

Terminated·NNorthwell Health·N/A·NCT00587847·12 enrolled

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00462332·86 enrolled

Lymphoma2 trials

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00505921·27 enrolled

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01030900·50 enrolled

Mycosis Fungoides1 trial

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT00047060·5 enrolled

Advanced Hematologic Malignancies1 trial

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Completed·UUniversity of Chicago·Phase 1/2·NCT00943592·82 enrolled

10 more indications

Renal Transplantation1 trial

CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

Completed·EEMagnusson·Phase 4·NCT00246129·123 enrolled

Hematologic Malignancies1 trial

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

Terminated· Sanofi logo

Sanofi·Phase 1·NCT00113048·24 enrolled

Relapsed/Refractory1 trial

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT00077961·49 enrolled

CLL1 trial

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Completed·FFrench Innovative Leukemia Organisation·Phase 3·NCT00564512·178 enrolled

Stem Cell1 trial

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00416884·1 enrolled

Systemic Lupus Erythematosus1 trial

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Terminated·NNew York Medical College·Phase 1·NCT00684255·1 enrolled

Sickle Cell Disease1 trial

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

Recruiting·—·Phase 1·NCT07015684·24 enrolled

Stem Cell Transplant1 trial

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Terminated·—·Phase 1/2·NCT00579111·4 enrolled

Systemic Sclerosis1 trial

Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis

Withdrawn·—··NCT01639573

Severe Aplastic Anemia1 trial

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

Terminated·—·Phase 2·NCT00578903·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for Campath. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Campath compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Campath. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Sanofi

Campath

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Allogeneic Stem Cell Transplantation3 trials

Chronic Lymphocytic Leukemia2 trials

Lymphoma2 trials

Mycosis Fungoides1 trial

Advanced Hematologic Malignancies1 trial

Renal Transplantation1 trial

Hematologic Malignancies1 trial

Relapsed/Refractory1 trial

CLL1 trial

Stem Cell1 trial

Systemic Lupus Erythematosus1 trial

Sickle Cell Disease1 trial

Stem Cell Transplant1 trial

Systemic Sclerosis1 trial

Severe Aplastic Anemia1 trial

References

Drug Info

Quick Facts

Related News